The future of foreign investment in China drugs wholesale, retail, distribution and other areas of medicine circulation will be limited.

December 1, the new "Industrial Catalog for Foreign Investment" will be implemented, this directory of major concern of foreign capital into the way medical institutions have also made clear, will only be able to "joint venture and cooperation," form. And the majority of biopharmaceutical and medical device research and development production, still holding on to encourage foreign investment attitude.

New "directory" of the provisions of the drugs wholesale, retail and distribution industries to a certain restrictions on foreign investment, and stressed that "the establishment of more than 30 stores, sales from a number of providers of different types and brands of goods from China holding the chain" . At present, however, have several major domestic drug circulation enterprises with foreign capital has launched a comprehensive cooperation.

"Because had not seen the relevant supporting policies from the interpretative, nor do I know these new policies have been introduced before the cooperation will be affected." Kyushu-groups and to tell reporters. The joint venture, Guangzhou Pharmaceutical companies that: "limit the scope of foreign investment should only while holding a joint venture of cooperation should be not be affected."

The new "directory" limited "medical institutions is limited to joint ventures and investment cooperation," the industry pointed out that this policy may have short-term negative impact on certain, and there is no explanation of the relevant rules out matching, "including foreign Social capital, the pace will slow down to enter. "

More and more foreign investors optimistic about China's medical industry. Foreign media reports, there are nearly 60 billion U.S. dollars of capital in attention to China's medical market. But with the imminent implementation of the policy restrictions, access to capital is bound to slow down the pace.